The Society for Nuclear Medicine and Molecular Imaging (SNMMI) is challenging the Centers for Medicare & Medicaid Services (CMS) to expand coverage for Amyloid PET. CMS had previously issued a national coverage determination (NCD) analysis for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease. The letter with recommendations comes after continuous consultation with other stakeholders and response to requests for comment on the proposed decision. As of January 11, 2022, CMS had declared the therapy was to be covered. The decision would occur under coverage with evidence development (CED). SNNMI’s letter outlines several areas of opportunity for improvement when it comes to amyloid PET coverage.
With the current national coverage determination NCD 220.6.20, Medicare will only provide coverage for amyloid PET when it is administered in the setting of an approved clinical study under the Coverage with Evidence Development (CED) policy. According to SNNMI, “In the draft national coverage determination (NCD) on monoclonal antibodies, CMS proposes to provide the following coverage for amyloid PET:
For any CMS approved trials, or trials supported by the NIH, that include a beta amyloid positron emission tomography (PET) scan as part of the protocol, it has been determined that these trials also meet the CED requirements included in the Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease NCD (220.6.20), and one beta amyloid PET scan will be covered per patient, if the patient did not previously receive a beta amyloid PET scan.” The proposal is flawed because it incorrectly restricts access to the vital diagnostic data that is furnished by amyloid PET scans while creating “inefficiencies for study sponsors and patients.”
Another consequence is the potential for economic and emotional stress on patients who experience mild cognitive impairment and must devote time and resources to enrolling in a clinical trial prior to receiving a PET scan, “only to often find out after enrollment that they are not eligible to receive monoclonal antibodies because there is no beta-amyloid present in their brain.” Based on these flaws and more, the organization has advocated for a number of key improvements in a final NCD.
• Coverage existing prior to a patient deemed eligible for an approved study
The draft NCD dictates that amyloid PET coverage is restricted to the conditions where it is performed as part of the protocol for a study that adheres to CED requirements for coverage of monoclonal antibodies, essentially limiting coverage to patients enrolled in a clinical trial.
PET scans, they argue, provide critical information to assess whether the patient meets specific criteria, evaluating whether the patient actually has amyloid pathology that may align with Alzheimer’s disease (AD). The patient must be actively in the trial if study sponsors want to obtain data that assess if a patient is a candidate for therapy and ultimately a candidate for a clinical trial.
SNNMI notes that “This requirement is illogical, highly inefficient, and will create significant burdens for both trial sponsors and patients. Enrolling patients in a clinical trial, including obtaining the necessary informed consent agreement, requires substantial time and resources. It also requires educating the patient about the trial, the potential benefits of the study therapy, and the associated risks.”
The Amyloid PET allows the identification of any patients who will not receive benefit from aducanumab ahead of time while de-complicating the enrollment process for both patients and trial sponsors. The PET also makes patient care more efficient for those that don’t present with beta-amyloid since treating professionals and caregivers are free to concentrate on treatment methods that best match the patients’ needs.
Therefore, CMS should ultimately not restrict coverage purely to trial participants but must allow coverage of amyloid PET to ascertain whether the patient should be in the trial at all. According to SNMMI, “This will require that CMS finalize cover- age for one PET scan to all patients considered candidates for aducanumab. CMS could accomplish this by retiring the beta amyloid CED NCD or by establishing additional, non-CED coverage of beta amyloid PET as part of the monoclonal antibody NCD….we recommend that CMS retire NCD 220.6.20.”
With the letter providing strong reasoning for change, these are not all the arguments SNMMI has for coverage. Explore more regulatory, policy, and coding knowledge to master compliance and coding with our monthly Radiology Compliance Manager.
Information Sources:
http://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=39886
The Centers for Medicare & Medicaid Services (CMS) is once again proposing to eliminate the inpatient only list starting in January 2026, repeating the process
Today, in utilization news, there is a warning to any surgeons who may be reading this – or anyone who works with surgeons. You may
Please log in to your account to comment on this article.
Gain clarity and confidence in OB‑GYN coding with this expert‑led webcast featuring Stacey Shillito, CDIP, CPMA, CCS, CCS‑P, CPEDC, COPC. You’ll learn how to apply global maternity package rules accurately, select the right CPT codes for procedures and visits, and identify documentation gaps that lead to denials. With practical guidance and real examples, this session helps you strengthen compliance, reduce audit risk, and ensure accurate reimbursement for women’s health services.
Uncover essential coding insights with nationally recognized coding authority Kay Piper, RHIA, CDIP, CCS. Through ICD10monitor’s interactive, on‑demand webcast series, Kay walks you through the AHA’s 2026 ICD‑10‑CM/PCS Quarterly Coding Clinics, translating each update into practical, easy‑to‑apply guidance designed to sharpen precision, ensure compliance, and strengthen day‑to‑day decision‑making. Available shortly after each official release.
Uncover critical guidance on the ICD-10-CM/PCS code updates. Kay Piper reviews and explains ICD-10-CM/PCS coding guidelines in the AHA’s fourth quarter 2026 ICD-10-CM/PCS Coding Clinic in an easy to access on-demand webcast.
Uncover critical guidance on the ICD-10-CM/PCS code updates. Kay Piper reviews and explains ICD-10-CM/PCS coding guidelines in the AHA’s third quarter 2026 ICD-10-CM/PCS Coding Clinic in an easy to access on-demand webcast.
Federal auditors are intensifying their focus on inpatient psychiatric facilities, using advanced data analytics to spotlight outliers and pursue high‑dollar repayments. In this high‑impact webcast, Michael Calahan, PA, MBA, Compliance Officer and V.P., Hospital & Physician Compliance, breaks down what regulators are really targeting in IPF-PPS admissions, documentation, treatment and discharge planning. Attendees will learn practical steps to tighten processes, avoid common audit triggers and protect reimbursement and reduce the risk of multimillion-dollar repayment demands.
In this timely session, Stacey Shillito, CDIP, CPMA, CCS, CCS-P, CPEDC, COPC, breaks down the complexities of Medical Decision Making (MDM) documentation so providers can confidently capture the true complexity of their care. Attendees will learn practical, efficient strategies to ensure documentation aligns with current E/M guidelines, supports accurate coding, and reduces audit risk, all without adding to charting time.
Join Ronald Hirsch, MD, FACP, CHCQM for The PEPPER Returns – Risk and Opportunity at Your Fingertips, a practical webcast that demystifies the PEPPER and shows you how to turn complex claims data into actionable insights. Dr. Hirsch will explain how to interpret key measures, identify compliance risks, uncover missed revenue opportunities, and understand new updates in the PEPPER, all to help your organization stay ahead of audits and use this powerful data proactively.
Stay ahead of the 2026-2027 audit surge with “Top 10 Audit Targets for 2026-2027 for Hospitals & Physicians: Protect Your Revenue,” a high-impact webcast led by Michael Calahan, PA, MBA. This concise session gives hospitals and physicians clear insight into the most likely federal audit targets, such as E/M services, split/shared and critical care, observation and admissions, device credits, and Two-Midnight Rule changes, and shows how to tighten documentation, coding, and internal processes to reduce denials, recoupments, and penalties. Attendees walk away with practical best practices to protect revenue, strengthen compliance, and better prepare their teams for inevitable audits.
BLOOM INTO SAVINGS! Get 25% OFF during our spring sale through March 27. Use code SPRING26 at checkout to claim this offer.
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 1 with code CYBER25
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24
